Table 1

SLN: sentinel lymph node
Entire cohort Patients with positive SLN Patients with negative SLN p
Number 203* 44/197* (22%) 153/197* (78%)
Sex 0.2706
Men 100 (49.3%) 18 (41%) 76 (50%)
Women 103 (50.7%) 26 (59%) 77 (50%)
Mean age (+/− SD) 55.8 +/−15.6 52.0 +/−17.4 56.6 +/−15.0 0.0864
Localization 0.1483
Trunk 74 (36.5%) 17 (38.6%) 54 (35.3%)
Upper limb 39 (19.2%) 3 (6.8%) 33 (21.6%)
Lower limb 63 (31.0%) 16 (36.4%) 47 (30.7%)
Hands and feet 27 (13.3%) 8 (18.2%) 19 (12.4%)
Type 0.6978
Superficial 115 (56.6%) 25 (56.8%) 86 (56.2%)
Nodular 39 (19.2%) 6 (13.6%) 31 (20.3%)
Acral 17 (8.4%) 4 (9.1%) 13 (8.5%)
Other 32 (15.8%) 9 (20.5%) 23 (15.0%)
Mean tumor thickness (range) 1.88 (0.4 - 10.1) 2.8 (1.2 - 10) 1.6 (0.4 - 10.1) 0.0289
T stage[2] 0.0172
T1 10 (4.9%) 0 10 (6.5%)
T2 101 (49.7%) 15 (34.1%) 83 (54.3%)
T3 55 (27.1%) 17 (38.6%) 36 (23.5%)
T4 33 (16.3%) 11 (25.0%) 21 (13.7%)
Incalculable1 4 (2.0%) 1 (2.3%) 3 (2.0%)
Clark level 0.3677
I 1 (0.5%) 0 1 (0.7%)
II 10 (4.9%) 2 (4.5%) 8 (5.2%)
III 56 (27.6%) 9 (20.5%) 46 (30.1%)
IV 100 (49.3%) 26 (59.1%) 70 (45.7%)
V 12 (5.9%) 4 (9.1%) 7 (4.6%)
Unknown 24 (11.8%) 3 (6.8%) 21 (13.7%)
Ulceration 0.0080
Yes 60 (29.6%) 21 (47.7%) 37 (24.2%)
No 131 (64.5%) 20 (45.5%) 107 (69.9%)
Unknown 12 (5.9%) 3 (6.8%) 9 (5.9%)

NS: not significant.

*6 complete or partial failures (lymphoscintigraphy and surgery).

Biver-Dalle et al.

Biver-Dalle et al. BMC Dermatology 2012 12:21   doi:10.1186/1471-5945-12-21

Open Data